Advertisement

Current Dermatology Reports

, Volume 7, Issue 2, pp 84–90 | Cite as

Use of Dermoscopy to Diagnose and Select BCCs that can be Treated Empirically

  • Chrysoula Papageorgiou
  • Zoe Apalla
  • Efstratios Vakirlis
  • Elena Sotiriou
  • Dimitrios Ioannides
  • Aimilios Lallas
Skin Cancer (A Marghoob and M Marchetti, Section Editors)
  • 37 Downloads
Part of the following topical collections:
  1. Topical Collection on Skin Cancer

Abstract

Purpose of Review

The diagnostic value of dermoscopy for basal cell carcinomas (BCCs) is well established. This paper aims to review available data on the role of dermoscopy not only in the management of BCCs in everyday practice and mainly in selecting tumors that may be treated non-surgically.

Recent Findings

Several factors influence the selection of treatment for BCC, including the histopathologic subtype, tumor depth, the presence of pigmentation or ulceration, the anatomic site, and patient’s physical profile. Dermoscopy was shown to provide additional information to the naked eye examination about several of these parameters and, therefore, might be very helpful tool in the pre-operative and post-treatment evaluation of BCCs.

Summary

In addition to its well-documented value in diagnosis, dermoscopy also gains ground in management of BCC. By revealing features not clinically seen, dermoscopy is a useful guide that enhances the selection of the appropriate treatment strategy and the assessment of post-treatment response.

Keywords

Basal cell carcinoma Dermoscopy Management Treatment Non-ablative therapies 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–79. This review article provides a thorough description of the pathogenetic, epidemiologic, clino-histopathologic features as well as the management options of BCC . PubMedPubMedCentralGoogle Scholar
  2. 2.
    • Bichakjian CK, Olencki T, Aasi SZ, et al. Basal cell skin cancer, Version 1.2016, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(5):574–97. This article provides recommendations and guidance for selecting the appropriate treatment choice of BCCs based on patient-, lesion-, and disease-specific factors . CrossRefPubMedGoogle Scholar
  3. 3.
    Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. BMJ. 2004;329(7468):705.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg. 2005;58(6):795–805.CrossRefPubMedGoogle Scholar
  5. 5.
    Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol. 2003;148(2):195–202.CrossRefPubMedGoogle Scholar
  6. 6.
    Christensen E, Warloe T, Kroon S, Funk J, Helsing P, Soler AM, et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2010;24:505–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications—actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(5):536–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Menzies SW, Westerhoff K, Rabinovitz H, Kopf AW, McCarthy W, Katz B. Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol. 2000;136(8):1012–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Altamura D, Menzies SW, Argenziano G, Zalaudek I, Soyer HP, Sera F, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol. 2010;62(1):67–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Pan Y, Chamberlain AJ, Bailey M, Chong AH, Haskett M, Kelly JW. Dermatoscopy aids in the diagnosis of the solitary red scaly patch or plaque-features distinguishing superficial basal cell carcinoma, intraepidermal carcinoma, and psoriasis. J Am Acad Dermatol. 2008;59(2):268–74.CrossRefPubMedGoogle Scholar
  12. 12.
    Lallas A, Apalla Z, Argenziano G, Longo C, Moscarella E, Specchio F, et al. The dermatoscopic universe of basal cell carcinoma. Dermatol Pract Concept. 2014;4(3):11–24.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lallas A, Argenziano G, Zendri E, Moscarella E, Longo C, Grenzi L, et al. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther. 2013;13(5):541–58.CrossRefPubMedGoogle Scholar
  14. 14.
    Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Reggiani C, Zalaudek I, Piana S, Longo C, Argenziano G, Lallas A, et al. Fibroepithelioma of pinkus: case reports and review of the literature. Dermatology. 2013;226(3):207–11.CrossRefPubMedGoogle Scholar
  16. 16.
    Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. J Am Acad Dermatol. 2009;60(1):137–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Giacomel J, Lallas A, Argenziano G, Reggiani C, Piana S, Apalla Z, et al. Dermoscopy of basosquamous carcinoma. Br J Dermatol. 2013;169(2):358–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Demirtaşoglu M, İlknur T, Lebe B, et al. Evaluation of dermoscopic and histopathologic features and their correlations in pigmented basal cell carcinomas. J Eur Acad Dermatol Venereol. 2006;20:916–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Tabanlıoğlu Onan D, Şahin S, Gököz Ö, Erkin G, Çakır B, Elçin G, et al. Correlation between the dermatoscopic and histopathological features of pigmented basal cell carcinoma. J Eur Acad Dermatol Venereol. 2010;24:1317–25.CrossRefPubMedGoogle Scholar
  20. 20.
    • Lallas A, Tzellos T, Kyrgidis A, Apalla Z, Zalaudek I, Karatolias A, et al. Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinoma. J Am Acad Dermatol. 2014;70(2):303–11. This diagnostic accuracy study evaluated the dermoscopic criteria associated with different BCC subtypes. CrossRefPubMedGoogle Scholar
  21. 21.
    Longo C, Lallas A, Kyrgidis A, Rabinovitz H, Moscarella E, Ciardo S, et al. Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy. J Am Acad Dermatol. 2014;71(4):716–724.e1.CrossRefPubMedGoogle Scholar
  22. 22.
    Themstrup L, De Carvalho N, Nielsen SM et al. In vivo differentiation of common basal cell carcinoma subtypes by microvascular and structural imaging using dynamic optical coherence tomography. Exp Dermatol 2017Google Scholar
  23. 23.
    Savoia P, Deboli T, Previgliano A, Broganelli P. Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma. Int J Mol Sci. 2015;16:23300–17.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Stebbins WG, Hanke CW. MAL-PDT for difficult to treat nonmelanoma skin cancer. Dermatol Ther. 2011;24:82–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011;25:896–901.CrossRefPubMedGoogle Scholar
  26. 26.
    Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149:1242–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Arits AHHM, Mosterd K, Essers BAB, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14:647–54.CrossRefPubMedGoogle Scholar
  28. 28.
    Apalla Z, Lallas A, Sotiriou E, Ioannides D. Effect of pigmentation on photodynamic therapy. Lancet Oncol. 2013;14:e339–40.CrossRefPubMedGoogle Scholar
  29. 29.
    Tan W-P, Tan AW-H, Ee H-L, Kumarasinghe P, Tan SH. Melanization in basal cell carcinomas: microscopic characterization of clinically pigmented and non-pigmented tumours. Australas J Dermatol. 2008;49:202–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Lallas A, Argenziano G, Kyrgidis A, Apalla Z, Moscarella E, Longo C, et al. Dermoscopy uncovers clinically undetectable pigmentation in basal cell carcinoma. Br J Dermatol. 2014;170(1):192–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Urech M, Kyrgidis A, Argenziano G, Reggiani C, Moscarella E, Longo C, et al. Dermoscopic ulceration is a predictor of basal cell carcinoma response to imiquimod: a retrospective study. Acta Derm Venereol. 2017;97(1):117–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Peris K, Ferrari A, Fargnoli MC, et al. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma. Dermatol Surg. 2005;31:217–20.CrossRefPubMedGoogle Scholar
  33. 33.
    Micantonio T, Fargnoli MC, Piccolo D, Letter PK. Changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod. Dermatol Surg. 2007;33:1403–5.PubMedGoogle Scholar
  34. 34.
    Cuellar F, Vilalta A, Puig S, et al. Dermoscopy of early recurrent basal cell carcinoma. Arch Dermatol. 2008;144:1254.CrossRefPubMedGoogle Scholar
  35. 35.
    Diluvio L, Campione E, Paterno EJ, et al. Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. J Dermatol Treat. 2009;20:124–9.CrossRefGoogle Scholar
  36. 36.
    Fargnoli MC, Kostaki D, Piccioni A, et al. Dermoscopy in the diagnosis and management of non-melanoma skin cancers. Eur J Dermatol. 2012;22:456–63.PubMedGoogle Scholar
  37. 37.
    Husein-ElAhmed H, Fernandez-Pugnaire MA. Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod. An Bras Dermatol. 2016;91(6):764–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    • Apalla Z, Lallas A, Tzellos T, Sidiropoulos T, Lefaki I, Trakatelli M, et al. Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma. Br J Dermatol. 2014;170(4):809–15. This study suggests the utility of dermoscopy in the evaluation of treatment response and monitoring of sBCCs after nonablative therapies CrossRefPubMedGoogle Scholar
  39. 39.
    Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904–11.CrossRefPubMedGoogle Scholar
  40. 40.
    Kwon GP, Ally MS, Bailey-Healy I, Oro AE, Kim J, Chang AL, et al. Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016;75(1):213–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Chrysoula Papageorgiou
    • 1
  • Zoe Apalla
    • 1
  • Efstratios Vakirlis
    • 1
  • Elena Sotiriou
    • 1
  • Dimitrios Ioannides
    • 1
  • Aimilios Lallas
    • 1
  1. 1.First Department of DermatologyAristotle UniversityThessalonikiGreece

Personalised recommendations